Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,137.80 | 14.90 | 0.16% |
CAC 40 | 7,905.92 | 75.81 | 0.97% |
DAX 40 | 23,632.08 | 105.03 | 0.45% |
Dow JONES (US) | 46,381.54 | 66.27 | 0.14% |
FTSE 100 | 9,250.41 | 23.73 | 0.26% |
HKSE | 26,159.12 | 185.02 | -0.70% |
NASDAQ | 22,788.98 | 157.50 | 0.70% |
Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
NZX 50 Index | 13,136.54 | 5.00 | -0.04% |
S&P 500 | 6,693.75 | 0.00 | 0.00% |
S&P/ASX 200 | 8,845.90 | 14.30 | 0.16% |
SSE Composite Index | 3,821.83 | 6.74 | -0.18% |